At meeting held on 10 December 2024
The Board of Directors of Alkem Laboratories at its meeting held today i.e.10 December 2024 approved the transfer of the trade generics business of the Company as a going concern, on a slump sale basis, to Alkem Wellness, a wholly owned subsidiary of the Company, incorporated in India.
The transaction is proposed to be effected through a business transfer agreement and will be effective on or before 1 April 2025 or such other date as may be mutually agreed between the parties, subject to customary closing conditions.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
